Lakeshore Biopharma Co. Ltd.Preferred / convertible
13F holders, Q1 2026 (March 31)2holders −1
0new positions
1sold out
$0.00avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Lakeshore Biopharma Co. Ltd. in their 13F filings, down 1 from Q4 2025. 0 opened new positions and 1 sold out. The largest holders were Ancora Advisors LLC ($18) and SkyView Investment Advisors, LLC ($0).
- Company
- Lakeshore Biopharma Co. Ltd.
- Filed as
- SUMMIT HEALTHCARE ACQUISITION (Q1 2026)
- CUSIP
- G9845F117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $35 |
All 13F filers, Q4 2025 → Q1 2026: 5,000 shares sold, net −5,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Ancora Advisors LLC | — | No change | 5,050 | $18 |
| SkyView Investment Advisors, LLC | — | No change | 12,210 | $0 |
"% of holder's portfolio" is LAKESHORE BIOPHARMA CO LTD's weight in each manager's 13F, not the share of Lakeshore Biopharma Co. Ltd. the manager owns.